{"schema_version":"secwatch.filing_event.v1","accession":"0001420720-24-000015","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.342178+00:00","generated_at":"2026-06-04T04:26:10.057916+00:00","sec_items":["1.01","3.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"iBio raises ~$15.1M in PIPE at $2.85/unit (148% premium), extends cash runway through FY2025","bullets":["Gross proceeds of ~$15.1M from common shares, pre-funded warrants, and Series E warrants at $2.85 per unit.","Net proceeds of ~$14.1M; intended for R&D and working capital, extending cash runway through fiscal 2025.","Series E warrants exercisable after 6 months at $2.64/share for 5 years; $2.85 price represents 148% premium to last close.","Amended credit agreement with Woodforest National Bank, extending term loan maturity to May 15, 2024.","Q3 FY2024 saw exercise of 1,131,500 Class C and 1,006,500 Class D warrants; shares outstanding now 8,515,226."],"urls":{"canonical":"https://secwatch.observer/filing/0001420720-24-000015","json":"https://secwatch.observer/filing/0001420720-24-000015.json","markdown":"https://secwatch.observer/filing/0001420720-24-000015.md","text":"https://secwatch.observer/filing/0001420720-24-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000142072024000015/0001420720-24-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000142072024000015/ibio-20240326x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:26:10.057916+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"62b67157dc09b171d94a81b5dc6e32b348e1927e","claim":"iBio, Inc. entered into Purchase Agreement with several institutional investors and an accredited investor valued at gross proceeds of approximately $15.1 million (effective 2024-03-26).","evidence_excerpt":"On March 26, 2024, iBio, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with several institutional investors and an accredited investor (the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement”) of the following securities for gross proceeds of approximately $15.1 million","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072024000015/0001420720-24-000015-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"several institutional investors and an accredited investor"},{"label":"Value","value":"gross proceeds of approximately $15.1 million"},{"label":"Effective","value":"2024-03-26"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}